Selux Diagnstics, a Boston, MA-based company developing precision diagnostics for infectious diseases, raised $50M in Series C funding.
The round was led by RA Capital Management, with participation from Sands Capital, Schooner Capital and Northpond Ventures.
The company intends to use the funds for the U.S. commercial launch of its Phenotyping (NGP) rapid Antimicrobial Susceptibility Testing (AST) platform.
Led by CEO Steve Lufkin, Selux Diagnostics is advancing a platform that provides automated AST results, enabling same-shift susceptibility testing of up to 50 antibiotics in parallel, and fast-tracking targeted patient therapies so patients can receive the treatments they need on day one. The platform is driven by its proprietary technologies, which differentiate antibiotic-induced bacterial growth modes through the interplay of novel biochemical assays and artificial intelligence.
In September 2021, the company received Breakthrough Device Designation from the FDA for positive blood culture and sterile body fluid sample indications for NGP. In October 2021, they received a $2.8 million award from the U.S. National Institutes of Health (NIH) to help commercialization efforts.
FinSMEs
01/03/2022